Next Article in Journal
Cytokines in Cancer Immunotherapy
Next Article in Special Issue
Transcription Inhibition as a Therapeutic Target for Cancer
Previous Article in Journal
The Expression of MTUS1/ATIP and Its Major Isoforms, ATIP1 and ATIP3, in Human Prostate Cancer
Previous Article in Special Issue
An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(4), 3838-3855;

Targeted Radionuclide Therapy

Department of Diagnostic Radiology, School of Medicine, Yale University, 333 Cedar St., New Haven, CT 06520, USA
Author to whom correspondence should be addressed.
Received: 22 August 2011 / Revised: 27 September 2011 / Accepted: 27 September 2011 / Published: 11 October 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
Full-Text   |   PDF [289 KB, uploaded 11 October 2011]


Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose. View Full-Text
Keywords: targeted radiotherapy; radionuclide; radioimmunotherapy targeted radiotherapy; radionuclide; radioimmunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Ersahin, D.; Doddamane, I.; Cheng, D. Targeted Radionuclide Therapy. Cancers 2011, 3, 3838-3855.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top